Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Bill Would Expand Rx Market, But Negatives Draw PhRMA's Protest

Executive Summary

The House health care reform bill contains a number of provisions that would greatly expand the market for pharmaceuticals, but the bill seeks a number of financial concessions from pharmaceutical manufacturers, prompting a statement of protest from the industry association

You may also be interested in...



DTC Drug Ad Tax Deductibility Proposal Supported By Finance Committee Member

Key Finance Committee member Nelson will offer amendment that would deny tax deduction for DTC drug ads.

Part D Mandated Rebates: CBO Weighs In On Likely Premium Increases

Medicare Part D premiums would be 5 percent higher in 2011 - and about 20 percent higher in 2019 - than they would be under current law if Part D revisions included in the House Tri-committee health reform bill are enacted, according to the Congressional Budget Office

Part D Mandated Rebates: CBO Weighs In On Likely Premium Increases

Medicare Part D premiums would be 5 percent higher in 2011 - and about 20 percent higher in 2019 - than they would be under current law if Part D revisions included in the House Tri-committee health reform bill are enacted, according to the Congressional Budget Office

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS051284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel